Data as of Sep 13, 2026. Both funds on the fields they both publish, from the same sources.
VBK vs XBI: how they differ
VBK and XBI hold 0% of their weight in the same names, and XBI returned more over the year.
Vanguard Small-Cap Growth Index Fund and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, VBK and XBI hold 0% of their money in the same securities at the same weight.
| Only in VBK | Only in XBI |
|---|---|
| Credo Technology Group Holding Ltd 1.27% | MODERNA INC 2.87% |
| REVOLUTION Medicines Inc 1.07% | TWIST BIOSCIENCE CORP 1.81% |
| Astera Labs Inc 1.05% | HALOZYME THERAPEUTICS INC 1.47% |
| Natera Inc 1.04% | NATERA INC 1.46% |
| Twilio Inc 0.88% | KYMERA THERAPEUTICS INC 1.45% |
| Casey's General Stores Inc 0.83% | TRAVERE THERAPEUTICS INC 1.40% |
| Carpenter Technology Corp 0.82% | ROIVANT SCIENCES LTD 1.39% |
| Curtiss-Wright Corp 0.79% | ORUKA THERAPEUTICS INC 1.38% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and Sep 10, 2026.
| VBK Vanguard Small-Cap Growth Index Fund | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Vanguard | State Street |
| What it is | Small-Cap Growth | SPDR S&P Biotech |
| Total return, 1 year | +13.8% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −3.7 pts | +46.5 pts |
| Expense ratio | 0.05% | 0.35% |
| Already in the S&P 500 | 10.2% | 8.5% |
| Holdings | 545 | 154 |
VBK in plain words
VBK is an index equity fund tracking the Small-Cap Growth. Over the year to Sep 11, 2026 it returned +13.8% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.05% a year. By its holdings filed for Jun 30, 2026, 10% of the fund by weight is stocks the S&P 500 also holds, across 545 positions, with the top ten at 9.3%. It sat 7.0% below its high of Aug 17, 2026 on Sep 11, 2026.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Sep 10, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 154 positions, with the top ten at 15.9%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, VBK or XBI?
- In the year to Sep 13, 2026, with distributions reinvested, VBK returned +13.8% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, VBK or XBI?
- VBK charges 0.05% a year and XBI charges 0.35%, so VBK is cheaper. Fees come from each fund's prospectus.
- How much do VBK and XBI overlap with the S&P 500?
- By their latest filed holdings, 10% of VBK and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, VBK against XBI, data as of Sep 13, 2026. https://etfiq.com/compare/any/vbk-vs-xbi Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources